ArticleScience translational medicine2020
Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy.
Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 182 citations in OpenAlex.
- Nanoengineered STING agonists for cancer therapy: toward immunodynamic control.Journal of hematology & oncology · 2026Review
- Ultra-slow release of hydrophilic drugs via multilamellar-multivesicular liposomes formed by unsaturated phospholipids.Nature biomedical engineering · 2026Article
- In Vitro Release Testing for Long Acting Injectables - a Workshop Summary Report.The AAPS journal · 2026Article
- Enhanced antitumor immunity of mRNA vaccines by bioorthogonal-like delayed activation of exogeneous STING.Nature biotechnology · 2026Article
- Radiopaque microsphere-hydrogel composite for extended-release intratumoral immunotherapy in a large animal model.Drug delivery and translational research · 2026Article
- Engineered Lipid Nanoparticles with Promoted Endosomal Escape and R283S-Mediated Stimulator of Interferon Genes (STING) Activation for Pancreatic Cancer Immunotherapy.Pharmaceutics · 2026Article
- Thermosensitive citrate-based mussel-inspired attack-defense integrated bioadhesives facilitate complicated wound healing.Bioactive materials · 2026Article
- Nanoparticulate Immunoactive Complex for Local Chemoimmunotherapy: From Murine Models to Pilot Canine Study.Cancer research communications · 2026Article
- Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles.Journal of functional biomaterials · 2026Review
- Ionic-Bionic Interfaces: Advancing Iontronic Strategies for Bioelectronic Sensing and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Controlled delivery of STING agonist and manganese ion in injectable PLGA implants for enhanced cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- The cGAS-STING pathway in cancer immunotherapy: prognostic value and therapeutic potential.Frontiers in immunology · 2026Review
- STING activation in renal and prostatic inflammation: potential therapeutic targets and immune regulation.Frontiers in immunology · 2026Review
- Working towards a single-dose vaccine for rabies post-exposure prophylaxis.Future virology · 2026Article
- A Biologically Inert Tamoxifen-derived Long-lasting Hydrogel-mediated Immunochemotherapy Can Mitigate Tumour Progression and Activate T Cell Immunity.Chemistry of materials : a publication of the American Chemical Society · 2025Article
- Advances in PLGA-based polymeric nanocarriers for colorectal cancer therapy: overcoming chemoresistance through controlled delivery strategies.Molecular cancer · 2025Review
- Enhanced Control of Liposomal Drug Release by Drug-Aptamer Complexes.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- STINGing Cancer: Development, Clinical Application, and Targeted Delivery of STING Agonists.International journal of molecular sciences · 2025Review
- Emerging cGAS-STING Agonist-Based Nanotherapeutics: Mechanistic Insights and Applications in Cancer Combination Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Polyanhydride-Based Microparticles for Programmable Pulsatile Release of Diphtheria Toxoid (DT) for Single-Injection Self-Boosting Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
Abstract
Activation of the stimulator of interferon gene (STING) pathway within the tumor microenvironment has been shown to generate a strong antitumor response. Although local administration of STING agonists has promise for cancer immunotherapy, the dosing regimen needed to achieve efficacy requires frequent intratumoral injections over months. Frequent dosing for cancer treatment is associated with poor patient adherence, with as high as 48% of patients failing to comply. Multiple intratumoral injections also disrupt the tumor microenvironment and vascular networks and therefore increase the risk of metastasis. Here, we developed microfabricated polylactic-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.